ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026
Inflammatory mediators of mRNA vaccine-induced adverse reactions in mice.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
mRNA vaccines are promising vaccine modalities against infectious diseases. However, these vaccines frequently cause adverse reactions, such as fever and fatigue, which are exacerbated after a booster dose, leading to vaccine hesitancy. Here, we elucidated the mechanisms underlying adverse reactions in mice after prime and boost vaccinations with mRNA vaccines. The mRNA vaccine induced systemic adverse reactions, such as fever, and local adverse reactions, such as enhanced vascular permeability, at the vaccination site in mice. Lipid nanoparticles (LNPs) used for mRNA encapsulation mainly contributed to these adverse reactions. We identified IL-1, IL-6, TNF-α, and type 1 IFN as key cytokines and COX-2 and PGE2 as inflammatory mediators responsible for systemic adverse reactions. TNF-α levels were enhanced after the boost vaccination by IFN-γ secreted from prime-vaccination-induced T cells, contributing to systemic adverse reactions. In addition, local adverse reactions at the vaccination site were caused by a mechanism different from that of systemic adverse reactions. We also found that the inhibition of IL-6 effectively reduced the adverse reactions while maintaining the vaccine effects. These data provide basic information for understanding adverse reactions in humans and may be useful for developing mRNA vaccines with fewer adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.